Disc Medicine, Inc. (NASDAQ: IRON) reported a net loss of $63.5 million for the quarter ended March 31 2026, a widening from the $34.09 million loss recorded in the same period a year earlier. The company’s basic and diluted loss per share both stood at $1.65, compared with $1.02 a year ago, and slightly below the consensus estimate of $1.645 for the quarter.
The broader loss was driven by a sharp rise in research and development spending, which climbed to $45.9 million from $27.8 million in Q1 2025, and by a doubling of selling, general and administrative expenses to $23.6 million from $12.2 million. These increases reflect the company’s intensified investment in its pipeline, including the progression of DISC‑0974 and DISC‑3405 programs and the expansion of infrastructure needed for future commercialization.
Cash and liquidity remain strong, with $730.2 million in cash and cash equivalents on hand as of March 31 2026, giving the company a projected runway into 2029. The company’s management highlighted that the widened loss is a deliberate, capital‑intensive phase of development rather than a sign of operational distress.
"We continue to make strong progress across the portfolio, completing enrollment in our Phase 3 trial of bitopertin in EPP and remaining on track to report topline data in the fourth quarter of this year. We were also pleased to have our Phase 2 data for DISC‑0974 in MF anemia selected for oral presentation at ASCO, while continuing to advance multiple additional clinical trials across our pipeline," said CEO John Quisel. "Together, these milestones reflect the strength of our execution and position us to deliver multiple important catalysts in the second half of this year."
The company’s earnings miss of $0.005 per share relative to analyst expectations was modest, and the absence of product revenue is consistent with its clinical‑stage status. A key regulatory hurdle remains: a Complete Response Letter was issued by the FDA for bitopertin in February 2026, and a Type A meeting is scheduled for Q2 2026 to discuss a resubmission strategy. The company also noted that enrollment in the Phase 3 APOLLO study for bitopertin has been completed, with topline data expected in Q4 2026, and that DISC‑0974 Phase 2 data will be presented at ASCO with full‑study results anticipated later in the year.
The results underscore Disc Medicine’s continued focus on pipeline development and capital allocation, while the strong cash position and upcoming clinical milestones provide a foundation for future progress. The company’s financial trajectory remains heavily weighted toward investment, with the widened loss reflecting deliberate spending to advance its portfolio rather than a deterioration in operational performance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.